Preventing CMV with letermovir after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Infections clinical trials.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are scheduled to have a stem cell transplant from a donor who is a good match.
- You or your donor has had CMV in the past (CMV-positive blood test).
- You have no CMV in your blood right now (tested within 5 days before starting).
- You have good kidney and liver function, and your heart and lungs work well enough for the transplant.
- You have not taken certain antiviral drugs (like ganciclovir, valganciclovir) in the past week or certain others in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This study checks whether certain virus levels in your blood after a stem cell transplant can help predict or prevent CMV infection. It aims to improve how doctors monitor and protect patients from this virus.
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Hear when a new CMV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.